简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
Latest
17:00
【Knowledge Atlas(02513.HK): Launches IPO on December 30, proposing to globally offer 37.4195 million H shares】Knowledge Atlas(02513.HK) announced that it will conduct an IPO from December 30, 2025 to January 5, 2026, planning to globally offer 37.4195 million H shares, with an offer price of HK$116.20 per share. The H shares are expected to start trading on the Hong Kong Stock Exchange at 9:00 a.m. on January 8, 2026.
Tag:
Knowledge Atlas
02513.HK
IPO
IPO Offering
Share:
17:00
【NewTimeSpace Hong Kong Stock Market Close | Three Major Indices Fluctuate and Strengthen, Hang Seng Index Closes Up 0.86%, Robotics, Semiconductors and Other Sectors Lead Gains】On December 30, 2025, Hong Kong's three major indices fluctuated and strengthened. The Hang Seng Index closed up 0.86%, the Hang Seng Tech Index rose 1.74%, and the Hang Seng China Enterprises Index climbed 1.12%. The total market trading volume reached HK$199.769 billion, with a net outflow of HK$3.845 billion in Southbound Capital.
Tag:
Hang Seng Index
NewTimeSpace
Share:
Previous
1..
230
231
232
233
234
234
pages total
Featured News
Finance
China Longyuan Power (00916.HK): Implementation of 2025 Equity Distribution, Final Dividend of RMB 0.625 per 10 Shares
Finance
Shenwan Hongyuan (06806.HK): Subsidiary’s RMB 3.6 Billion Corporate Bonds Listed on Shenzhen Stock Exchange
Finance
New Focus (00360.HK): Appointment of Hord Capital as Independent Financial Adviser
Finance
China Everbright Greentech (01257.HK): Entered Framework Agreements for Hazardous Waste Disposal Services Covering 2026 to 2028
Finance
Muyuan Co., Ltd. (02714.HK): Completes Corporate Name Change
Finance
CGII HLDGS (01940.HK): Completion of Loan Assignment
Finance
Guofu Hydrogen Energy (02582.HK): H-share Full Circulation Granted Listing Approval by HKEX
Finance
Wise Wealth Resources Investment (00007.HK): Appointment of Hao Xiaohui as Executive Director and Co-Chairman, Xu Shiping Re-designated as Co-Chairman
Finance
Fosun Pharma (02196.HK): Controlled Subsidiary’s HLX3902 Injection Obtains Clinical Trial Approval
Finance
Xunhe Group (01591.HK): Expected Annual Loss to Widen to HK$13 Million – HK$16 Million
Scan QR Code
Download App
×
Share to WeChat
Open WeChat, use "Scan," and share to my Moments